Document Detail


Mediator antagonists in the treatment of allergic disease.
MedLine Citation:
PMID:  11715214     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
New approaches to allergic inflammation include specific cytokine antagonists and monoclonal antibodies against IgE, against chemokines, and against adhesion molecules. Currently available therapies, such as leukotriene antagonists, may soon be approved for allergic rhinitis. New generation antihistamines such as desloratadine have wide-ranging anti-allergic, anti-inflammatory profiles, including suppression of cytokine, chemokine, and adhesion molecule expression. Recent desloratadine studies have demonstrated that this highly potent H1 receptor antagonist consistently provides relief of nasal congestion and may provide benefits similar to montelukast in mild asthma patients. New generation intra-nasal corticosteroids such as fluticasone and mometasone provide high corticosteroid potency while being minimally bioavailable when administered as intranasal preparations. Future advances in allergy therapy also include improved T-cell selective formats of immunotherapy. The range of therapies for allergic rhinitis is likely to substantially increase in the coming years.
Authors:
L M DuBuske
Related Documents :
20562264 - Regulation of th2 responses and allergic inflammation through bystander activation of c...
14702194 - The mast cell: an active participant or an innocent bystander?
18769204 - Immune regulatory mechanisms in allergic conjunctivitis: insights from mouse models.
11842304 - Scavenger receptor-specific allergen delivery elicits ifn-gamma-dominated immunity and ...
21878234 - Bile salt supplementation acts via the farnesoid x receptor to alleviate lipopolysaccha...
16157684 - Caspase-8 deficiency in t cells leads to a lethal lymphoinfiltrative immune disorder.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Allergy and asthma proceedings : the official journal of regional and state allergy societies     Volume:  22     ISSN:  1088-5412     ISO Abbreviation:  Allergy Asthma Proc     Publication Date:    2001 Sep-Oct
Date Detail:
Created Date:  2001-11-21     Completed Date:  2002-02-21     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9603640     Medline TA:  Allergy Asthma Proc     Country:  United States    
Other Details:
Languages:  eng     Pagination:  261-75     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anti-Allergic Agents / immunology,  therapeutic use*
Humans
Inflammation Mediators / antagonists & inhibitors*,  immunology,  therapeutic use*
Rhinitis / drug therapy*,  immunology
Chemical
Reg. No./Substance:
0/Anti-Allergic Agents; 0/Inflammation Mediators

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Genetic and cytological characterization of a developmental mutant of Aspergillus nidulans induced b...
Next Document:  The evolution of pharmacotherapy for rhinitis and urticaria.